Chargement en cours...
Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab. Two established xenograft models re...
Enregistré dans:
| Publié dans: | Mol Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528408/ https://ncbi.nlm.nih.gov/pubmed/23142657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.005 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|